BioMarin Q3 2026 net loss more than triples to USD 123 million

Bitget2026/11/02 21:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioMarin's third-quarter 2026 GAAP net loss more than tripled to $123 million year over year, primarily driven by Amicus acquisition costs.
Total revenues climbed 32% to $1.02 billion, primarily driven by acquired therapies and VIMIZIM growth.
The FDA set a May 30, 2027 target action date for VOXZOGO's potential expansion into hypochondroplasia.
Full-year 2026 total revenues guidance fell to $3.8 billion–$3.9 billion, reflecting uncertainty over international order timing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611021603PR_NEWS_USPR_____SF86326) on November 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioMarin Q3 2026 net loss more than triples to USD 123 million

You may also like

Crypto prices